In order to test the possibility that ATRi would further potentiate the radiation sensitivity of CRC cells after knock-down of ARID1B, a synthetic lethal partner of ARID1A, cells were treated with VE822 after transfection with siRNA targeting ARID1B. This evidence concerns the gene ARID1A and colorectal carcinoma.